DDInter1616 DDInter1016
Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Romidepsin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Romidepsin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nifedipine
Romidepsin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Histrelin
Romidepsin {u} may lead to a major life threatening interaction when taken with {v} Bacillus calmette-guerin substrain tice live antigen
Romidepsin {u} may lead to a major life threatening interaction when taken with {v} Halofantrine
Romidepsin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Romidepsin may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Romidepsin may lead to a major life threatening interaction when taken with Halofantrine